Product Overview
Dragon Pharma Sustanon 270 is a five-ester testosterone blend in a 10 ml multi-dose vial. Each millilitre carries testosterone acetate 20 mg, testosterone propionate 30 mg, testosterone phenylpropionate 60 mg, testosterone isocaproate 60 mg and testosterone decanoate 100 mg, which adds up to 270 mg per mL and 2700 mg of labelled hormone per vial, in an MCT oil carrier. The proportions work out as 7.4 percent acetate, 11.1 percent propionate, 22.2 percent phenylpropionate, 22.2 percent isocaproate and 37.0 percent decanoate.
The formula is the clinical four-ester reference taken one step further. That ancestor, sold as Sustanon 250, combines propionate, phenylpropionate, isocaproate and decanoate; this product keeps all four and sits 20 mg of acetate on top of them. The proportions are the design: acetate and propionate together are only 18.5 percent of the label and exist to lift the level within hours, the two middle esters at 22.2 percent each carry the plateau, and decanoate at 37.0 percent is the tail, with a terminal half-life in blood of about 5.6 days after a mixed-ester injection. The clinical mixture peaks at roughly 70 nmol/L of total plasma testosterone about 24 to 48 hours after a single 250 mg injection and falls back to the lower limit of the normal male range in about 21 days, which is the shape of the whole curve rather than of any one ester. The manufacturer profile rates the blend for high aromatization, high DHT conversion and severe HPTA suppression, which is what pure testosterone does at a cycle dose.
Because every ester releases the same hormone, this is one preparation rather than a stack of different drugs: the mixture is a delivery system, and what it changes is onset, injection frequency and clean-up time. That is what it is for: a mass, strength or recomposition cycle with one testosterone source and a slower release than a single short ester gives. Everything the cycle needs beyond it is support: an aromatase inhibitor for estradiol and a recovery plan for the axis. Testo Blend 350 and Testabol 400 are the brand's other multi-ester testosterone options, while Enantat 250 is the single-ester alternative. Quality is documented rather than assumed: the vendor posts an independent assay of 271.26 mg/mL on batch DA2S25, which is 100.47 percent of the label claim.
Dosage Protocol
No approved dose exists for this product. The clinical label for the four-ester ancestor is a reference point only, and its injection every three weeks is a replacement rather than a cycle schedule.
| Beginner | 270 mg per week, which is 1 mL split into two shots - 10 weeks |
| Intermediate | 400 to 600 mg weekly, given as two injections - 10 to 12 weeks |
| Advanced | 600 to 750 mg per week - 12 to 16 weeks; the band from the general testosterone material for this folder |
| Female | None on record; the sources checked offer no schedule for women, and virilization is the limiting risk |
| Administration | Injected into muscle twice weekly on the vendor's own 3 to 4 day interval, which keeps the fast end of the curve from peaking; move the site each time |
Other recorded bands do not match this table and none has been averaged in. The folder's general testosterone material lists a lower ladder of 250 to 350 mg weekly, then 400 to 600, then 600 to 750. A second vendor profile quotes a wider ladder - 250 to 500 mg weekly, then 500 to 750, and 750 to 1000 or beyond - and warns about injection discomfort at high concentration.
Suggested Protocols
The preparation carries only testosterone, so a cycle needs estradiol control and a recovery plan rather than a second base. Cards below open Dragon Pharma pages.
Support and recovery normally run through Arimidex or Aromasin for estradiol, then Nolvadex and Clomid after the last shot, with HCG 5000 IU for the closing weeks of a long cycle. A slower, drier run can be built around EQ 200 / Test E 200 instead of a second testosterone product.
What to Expect
- First 24 to 48 hours. The fast end of the curve is already releasing. A vendor profile describes effects becoming noticeable in this window, with blood levels rising long before the slow end contributes.
- Weeks 3 to 6. Strength, fullness and libido move on the usual testosterone timeline; water retention and blood pressure follow estradiol, not the esters.
- Between shots. Under twice-weekly dosing the middle of the curve holds the level first and the tail carries it after, which is the reason the schedule exists.
- Last shot to baseline. In the clinical four-ester reference, plasma testosterone is back at the lower limit of the normal range in about 21 days, and the same decanoate proportion is kept here.
- Estrogen. Esters do not change the fact that the hormone aromatizes, so any estrogenic effect is managed from blood work rather than guesswork.
- Limitation. The long tail means the cycle cannot be ended quickly, and the date of the last injection is what sets the start of PCT.
- Practical note. Injection pain is rated lower than on 350 to 400 mg/mL products, but oil volume still matters and sites should be rotated.
Side Effects and Management
Everything on this list comes from one source: a full cycle dose of testosterone that aromatizes, which is why management is built around blood work.
Post-Cycle Therapy
The tail of the curve decides when recovery can begin. The adjacent three-ester product page puts decanoate clearance at about three weeks, matching the upper end of the range below.
